Trial · NCT03043560
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Ventral Striatum (VS) Activation | Ezogabine | baseline | -0.26 | Standard Deviation 0.69 | Bold Oxygen-level Dependent (BOLD) Signa |
| Change in Ventral Striatum (VS) Activation | Placebo | baseline | 0.95 | Standard Deviation 0.79 | Bold Oxygen-level Dependent (BOLD) Signa |
| Change in Ventral Striatum (VS) Activation | Ezogabine | 5 weeks | 0.176 | Standard Deviation 0.81 | Bold Oxygen-level Dependent (BOLD) Signa |
| Change in Ventral Striatum (VS) Activation | Placebo | 5 weeks | 0.015 | Standard Deviation 0.68 | Bold Oxygen-level Dependent (BOLD) Signa |
| Change in Snaith-Hamilton Pleasure Scale (SHAPS) | Ezogabine | Baseline | 38.7 | Standard Deviation 8.1 | score on a scale |
| Change in Snaith-Hamilton Pleasure Scale (SHAPS) | Placebo | Baseline | 33.7 | Standard Deviation 6 | score on a scale |
| Change in Snaith-Hamilton Pleasure Scale (SHAPS) | Ezogabine | 5 weeks | 27.5 | Standard Deviation 8.5 | score on a scale |
| Change in Snaith-Hamilton Pleasure Scale (SHAPS) | Placebo | 5 weeks | 30 | Standard Deviation 10.9 | score on a scale |
| Clinical Global Impression - Improvement (CGI-I) | Ezogabine | baseline | 4 | Standard Deviation 0.2 | score on a scale |
| Clinical Global Impression - Improvement (CGI-I) | Placebo | baseline | 4 | Standard Deviation 0.4 | score on a scale |
| Clinical Global Impression - Improvement (CGI-I) | Ezogabine | 5 weeks | 2.1 | Standard Deviation 1 | score on a scale |
| Clinical Global Impression - Improvement (CGI-I) | Placebo | 5 weeks | 2.8 | Standard Deviation 1.3 | score on a scale |
| Clinical Global Impression - Severity (CGI-S) | Ezogabine | baseline | 4.4 | Standard Deviation 0.5 | score on a scale |
| Clinical Global Impression - Severity (CGI-S) | Placebo | baseline | 4.6 | Standard Deviation 0.6 | score on a scale |
| Clinical Global Impression - Severity (CGI-S) | Ezogabine | 5 weeks | 2.6 | Standard Deviation 1.2 | score on a scale |
| Clinical Global Impression - Severity (CGI-S) | Placebo | 5 weeks | 3.3 | Standard Deviation 1.2 | score on a scale |
| Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS) | Ezogabine | baseline | 46.1 | Standard Deviation 15.1 | score on a scale |
| Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS) | Placebo | baseline | 53.7 | Standard Deviation 15 | score on a scale |
| Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS) | Ezogabine | 5 weeks | 65.1 | Standard Deviation 22.8 | score on a scale |
| Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS) | Placebo | 5 weeks | 59 | Standard Deviation 23.5 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03043560/results